Adobe stock looks cheap at 12.4x earnings, but rising competition from Canva, Figma, and Apple may make ADBE a hold or value trap. See more here.
Objective To assess whether post-authorisation studies registered with the European Medicines Agency (EMA) adhere to legislation and recommendations to publicly post study protocols and results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results